⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20295503 | 1.00 | — | — | |
| SCHEMBL20295542 | 1.00 | — | — | |
| Diisopropanolamine SCHEMBL10618901 | 0.72 | — | — | |
| Diisopropanolamine SCHEMBL22774 | 0.72 | — | — | |
| SCHEMBL606663 | 0.72 | — | — | |
| Diisopropanolamine SCHEMBL6858463 | 0.69 | TSHR (0.41) | — | |
| SCHEMBL5478947 | 0.69 | — | — | |
| SCHEMBL20515147 | 0.69 | — | — | |
| SCHEMBL152642 | 0.69 | — | — | |
| SCHEMBL879230 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220194931-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2022-06-23 | — | — | US | claimed |
| CN-110582493-A | Benzoxazole derivatives as immunomodulators | 因赛特公司 | 2019-12-17 | — | — | CN | claimed |
| EP-3558985-A1 | BENZOOXAZOLE DERIVATIVES AS IMMUNOMODULATORS | Incyte Corporation (US) | 2019-10-30 | — | — | EP | claimed |
| WO-2018119266-A1 | BENZOOXAZOLE DERIVATIVES AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2018-06-28 | — | — | WO | claimed |
| US-20180179197-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | claimed |
| US-8202876-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2012-06-19 | — | — | US | claimed |
| US-20100029605-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-02-04 | — | — | US | claimed |
| EP-2057146-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-05-13 | — | — | EP | claimed |
| US-7452880-B2 | Substituted pyrazolo [3,4-d] pyrimidines and methods of using the same | F. HOFFMANN-LA ROCHE AG (CH) | 2008-11-18 | — | — | US | claimed |
| WO-2008042639-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-04-10 | — | — | WO | claimed |
| EP-1887007-A2 | Novel compounds | AstraZeneca AB (SE) | 2008-02-13 | — | — | EP | claimed |
| EP-1625126-B1 | IMIDAZO AND THIAZOLOPYRIDINES AS JAK3 KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-01-16 | — | — | EP | claimed |
| US-20060287355-A1 | Imidazo and thiazolopyridines as jak3 kinase inhibitors | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | US | claimed |
| CN-1784402-A | Imidazo and thiazolopyridines as JAK3 kinase inhibitors | ASTRAZENECA AB (SE) | 2006-06-07 | — | — | CN | claimed |
| EP-1625126-A1 | IMIDAZO AND THIAZOLOPYRIDINES AS JAK3 KINASE INHIBITORS | AstraZeneca AB (SE) | 2006-02-15 | — | — | EP | claimed |
| WO-2005109995-A2 | THERMOSTABLE GLUCONATE DEHYDRATASE AND USE THEREOF | POSCO (KR) | 2005-11-24 | — | — | WO | claimed |
| US-20050203091-A1 | Heteroaryl-fused pyrazolo derivatives and methods for using the same | ROCHE PALO ALTO LLC | 2005-09-15 | — | — | US | claimed |
| US-20050197340-A1 | Fused-pyrazolo pyrimidine and pyrazolo pyrimidinone derivatives and methods for using the same | ROCHE PALO ALTO LLC | 2005-09-08 | — | — | US | claimed |
| WO-2004099204-A1 | IMIDAZO AND THIAZOLOPYRIDINES AS JAK3 KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-11-18 | — | — | WO | claimed |
| CN-110582493-B | Benzoxazole derivatives as immunomodulators | 因赛特公司 | 2024-03-08 | — | — | CN | disclosed |
| US-11787793-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-10-17 | — | — | US | disclosed |
| US-11597699-B2 | MEK inhibitors and methods of their use | EXELIXIS, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| US-20220194931-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2022-06-23 | — | — | US | disclosed |
| US-11339149-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2022-05-24 | — | — | US | disclosed |
| CN-109053523-B | Azetidines as MEK inhibitors for the treatment of proliferative diseases | 埃克塞利希斯股份有限公司 | 2022-03-25 | — | — | CN | disclosed |
| US-20210107900-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2021-04-15 | — | — | US | disclosed |
| US-10800768-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2020-10-13 | — | — | US | disclosed |
| CN-111643496-A | Methods of using MEK inhibitors | 埃克塞利希斯股份有限公司 | 2020-09-11 | — | — | CN | disclosed |
| US-20200283383-A1 | MEK Inhibitors and Methods of Their Use | EXELIXIS, INC. | 2020-09-10 | — | — | US | disclosed |
| US-20200031770-A1 | MEK INHIBITORS AND METHODS OF THEIR USE | EXELIXIS, INC. | 2020-01-30 | — | — | US | disclosed |
| CN-110668988-A | Azetidines as MEK inhibitors for the treatment of proliferative diseases | 埃克塞利希斯股份有限公司 | 2020-01-10 | — | — | CN | disclosed |
| CN-110582493-A | Benzoxazole derivatives as immunomodulators | 因赛特公司 | 2019-12-17 | — | — | CN | disclosed |
| EP-3558985-A1 | BENZOOXAZOLE DERIVATIVES AS IMMUNOMODULATORS | Incyte Corporation (US) | 2019-10-30 | — | — | EP | disclosed |
| CN-104892582-B | Azetidine as the mek inhibitor for treating proliferative disease | 埃克塞利希斯股份有限公司 | 2019-09-27 | — | — | CN | disclosed |
| US-20190225601-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2019-07-25 | — | — | US | disclosed |
| US-10308644-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2019-06-04 | — | — | US | disclosed |
| US-20190144382-A1 | MEK Inhibitors and Methods of Their Use | EXELIXIS, INC. | 2019-05-16 | — | — | US | disclosed |
| CN-109053523-A | Azetidine as the mek inhibitor for treating proliferative disease | 埃克塞利希斯股份有限公司 | 2018-12-21 | — | — | CN | disclosed |
| EP-2101759-B1 | METHODS OF USING MEK INHIBITORS | EXELIXIS INC (US) | 2018-10-10 | — | — | EP | disclosed |
| WO-2018119266-A1 | BENZOOXAZOLE DERIVATIVES AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2018-06-28 | — | — | WO | disclosed |
| US-20180179197-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| CN-103524392-B | As for treating the azetidine of the MEK inhibitor of proliferative disease | 埃克塞利希斯股份有限公司 | 2018-06-01 | — | — | CN | disclosed |
| US-20170166523-A9 | MEK Inhibitors And Methods Of Their Use | EXELIXIS, INC. | 2017-06-15 | — | — | US | disclosed |
| CN-105106199-A | Methods of using MEK inhibitors | EXELIXIS INC | 2015-12-02 | — | — | CN | disclosed |
| CN-104892582-A | AZETIDINES AS MEK INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | EXELIXIS INC | 2015-09-09 | — | — | CN | disclosed |
| US-20150141399-A1 | MEK Inhibitors And Methods Of Their Use | EXELIXIS INC (US) | 2015-05-21 | — | — | US | disclosed |
| US-20140275527-A1 | Azetidines as MEK Inhibitors for the Treatment of Proliferative Diseases | EXELIXIS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| CN-103524392-A | Azetidines as mek inhibitors for the treatment of proliferative diseases | EXELIXIS INC | 2014-01-22 | — | — | CN | disclosed |
| CN-101365676-B | Azetidines as mek inhibitors for the treatment of proliferative diseases | EXELIXIS INC | 2013-09-11 | — | — | CN | disclosed |
| US-8362002-B2 | Azetidines as MEK inhibitors for the treatment of proliferative diseases | EXELIXIS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8202876-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2012-06-19 | — | — | US | disclosed |
| US-20110263558-A1 | Azetidines as MEK Inhibitors for the Treatment of Proliferative Diseases | EXELIXIS, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-7999006-B2 | Anticancer agents; mitogen-activated protein kinases (MEK) | EXELIXIS, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| EP-1934174-B1 | AZETIDINES AS MEK INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | EXELIXIS INC (US) | 2011-04-06 | — | — | EP | disclosed |
| US-7915250-B2 | Azetidines as MEK inhibitors for the treatment of proliferative diseases | EXELIXIS, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-20100249096-A1 | anticarcinogenic agent; 1-({4-[(2-fluoro-4-iodophenyl)amino]-3-thienyl}carbonyl)azetidin-3-amine | EXELIXIS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-7803839-B2 | anticarcinogenic agent; 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-carbonyl)azetidin-3-ol | EXELIXIS, INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-20100029605-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-02-04 | — | — | US | disclosed |
| EP-2101759-A1 | METHODS OF USING MEK INHIBITORS | Exelixis, Inc. (US) | 2009-09-23 | — | — | EP | disclosed |
| US-20090156576-A1 | anticarcinogenic agent; 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-carbonyl)azetidin-3-ol | EXELIXIS INC. (US) | 2009-06-18 | — | — | US | disclosed |
| EP-2057146-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-05-13 | — | — | EP | disclosed |
| CN-101365676-A | Azetidines as mek inhibitors for the treatment of proliferative diseases | EXELIXIS INC (US) | 2009-02-11 | — | — | CN | disclosed |
| US-7452880-B2 | Substituted pyrazolo [3,4-d] pyrimidines and methods of using the same | F. HOFFMANN-LA ROCHE AG (CH) | 2008-11-18 | — | — | US | disclosed |
| WO-2008124085-A2 | METHODS OF USING COMBINATIONS OF MEK AND JAK-2 INHIBITORS | EXELIXIS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| US-7435731-B2 | Substituted pyrazolo[3,4-d]pyrimadines and methods of using the same | ROCHE PALO ALTO LLC (US) | 2008-10-14 | — | — | US | disclosed |
| US-20080166359-A1 | Methods of using MEK inhibitors | EXELIXIS, INC. | 2008-07-10 | — | — | US | disclosed |
| WO-2008076415-A1 | METHODS OF USING MEK INHIBITORS | EXELIXIS, INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008042639-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-04-10 | — | — | WO | disclosed |
| EP-1887007-A2 | Novel compounds | AstraZeneca AB (SE) | 2008-02-13 | — | — | EP | disclosed |
| EP-1625126-B1 | IMIDAZO AND THIAZOLOPYRIDINES AS JAK3 KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-01-16 | — | — | EP | disclosed |
| CN-1934111-A | Heteroaryl-fused pyrazolo derivatives | ROCHE PALO ALTO LLC (CH) | 2007-03-21 | — | — | CN | disclosed |
| CN-1926139-A | Fused pyrazole derivatives | HOFFMANN LA ROCHE (CH) | 2007-03-07 | — | — | CN | disclosed |
| EP-1737865-A1 | FUSED DERIVATIVES OF PYRAZOLE | F.HOFFMANN-LA ROCHE AG (CH) | 2007-01-03 | — | — | EP | disclosed |
| US-20060287355-A1 | Imidazo and thiazolopyridines as jak3 kinase inhibitors | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | US | disclosed |
| EP-1720878-A1 | HETEROARYL-FUSED PYRAZOLO DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-11-15 | — | — | EP | disclosed |
| CN-1784402-A | Imidazo and thiazolopyridines as JAK3 kinase inhibitors | ASTRAZENECA AB (SE) | 2006-06-07 | — | — | CN | disclosed |
| EP-1625126-A1 | IMIDAZO AND THIAZOLOPYRIDINES AS JAK3 KINASE INHIBITORS | AstraZeneca AB (SE) | 2006-02-15 | — | — | EP | disclosed |
| US-20050203091-A1 | Heteroaryl-fused pyrazolo derivatives and methods for using the same | ROCHE PALO ALTO LLC | 2005-09-15 | — | — | US | disclosed |
| WO-2005085248-A1 | HETEROARYL-FUSED PYRAZOLO DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2005-09-15 | — | — | WO | disclosed |
| WO-2005085249-A1 | FUSED DERIVATIVES OF PYRAZOLE | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-15 | — | — | WO | disclosed |
| US-20050197340-A1 | Fused-pyrazolo pyrimidine and pyrazolo pyrimidinone derivatives and methods for using the same | ROCHE PALO ALTO LLC | 2005-09-08 | — | — | US | disclosed |
| WO-2004099204-A1 | IMIDAZO AND THIAZOLOPYRIDINES AS JAK3 KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-11-18 | — | — | WO | disclosed |
| EP-0501693-B1 | Isoquinoline derivatives | BANYU PHARMA CO LTD (JP) | 1996-08-28 | — | — | EP | disclosed |
| US-5362736-A | Alkoxy derivatives for cardiovascular disorders | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1994-11-08 | — | — | US | disclosed |
| EP-0501693-A1 | Isoquinoline derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1992-09-02 | — | — | EP | disclosed |
| EP-0501693-A1 | Isoquinoline derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1992-09-02 | — | — | EP | disclosed |